Depression in alpha-synucleinopathies: Prevalence, pathophysiology and treatment

Journal of Neural Transmission, Supplement

Volumn , Issue 60, 2000, Pages 335-343

  Stefanova, N ^a   Seppi, K ^a   Scherfler, C ^a   Puschban, Z ^a   Wenning, G K ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LEVODOPA; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; OLANZAPINE; REBOXETINE; SELEGILINE; SERTRALINE;

CONFERENCE PAPER; DEPRESSION; ELECTROCONVULSIVE THERAPY; LEWY BODY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; SHY DRAGER SYNDROME;

EID: 0034522723     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6301-6_23     Document Type: Conference Paper

References (44)

1. Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA
2. Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression
3. Depression and Parkinson's disease: A review
4. ECT and Parkinson's disease revisited: A "naturalistic" study
5. Depressive symptoms in Parkinson's disease: A comparison with disabled control subjects
6. New approaches to the treatment of refractory depression
7. Affective symptoms in multiple system atrophy and Parkinson's disease: Response to levodopa therapy
8. Depression in Parkinson's disease: A quantitative and qualitative analysis
9. Sertraline for the treatment of depression in Parkinson's disease
10. Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease
11. Post mortem studies in Parkinson's disease - Is it possible to detect brain areas for specific symptoms?
12. Depression and Parkinson's disease: Possible role of serotonergic mechanisms
13. Deprenyl in Parkinson's disease
14. Recent advances in atypical parkinsonian disorders
15. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: A clinicopathologic study
16. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: A double-blind, placebo-controlled study
17. Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease
18. Depression in the patient with Parkinson's disease
19. Clinical and biochemical features of depression in Parkinson's disease
20. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
21. Effectiveness of ECT in patients with parkinsonism
22. The neurobiology of ECT: Animal studies
23. Depression in multiple system atrophy and in idiopathic Parkinson's disease: A pilot comparative study
24. Depression in Parkinson's disease: Impediments to recognition and treatment options
25. Antibody in the CSF of patients with multiple system atrophy reacts specifically with rat locus ceruleus
26. Demenz mit Lewy Körperchen
27. Depression in Parkinson's disease. A positron emission study
28. Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia
29. Monoaminergic actions of ECT
30. Electroconvulsive therapy
31. Dementia with Lewy bodies versus pure Alzheimer disease: Differences in cognition, neuropathology, cholinergic dysfunction, and synapse density
32. Coexisting dementia and depression in Parkinson's disease
33. Parkinson's disease with depression: A possible subgroup of idiopathic parkinsonism
34. Disease progression of dementia with Lewy bodies: A clinicopathological study
35. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies
36. Depression in patients with early versus late onset of Parkinson's disease
37. Cognitive impairments and depression in Parkinson's disease: A follow up study
38. Moclobemide and selegeline in the treatment of depression in Parkinson's disease
39. The occurrence of depression in Parkinson's disease. A community-based study
40. Bromocriptine and imipramine in endogenous depression. A double-blind controlled trial in out-patients
41. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
42. Olanzapine in dementia with Lewy bodies: A clinical study
43. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases
44. Clinicopathological study of 35 cases of multiple system atrophy